All Updates

All Updates

icon
Filter
M&A
Arbor Biotechnologies acquires Serendipity Biosciences to expand gene-editing capabilities
Human Gene Editing
May 8, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Human Gene Editing

Human Gene Editing

May 8, 2024

Arbor Biotechnologies acquires Serendipity Biosciences to expand gene-editing capabilities

M&A

  • Massachusetts-based AI-powered gene-editing company Arbor Biotechnologies has acquired gene-editing technology provider Serendipity Biosciences to enhance the development of novel gene-editing treatments and expand Arbor's genomic medicine portfolio. Financial details of the acquisitions were not disclosed.

  • Serendipity’s gene-editing assets, including genome editing based on RNA-guided endonuclease proteins Fanzor, IsrB, and other editing technologies, will help discover novel therapeutic applications for Arbor’s genomic medicine portfolio. Post-acquisition, Arbor Biotechnologies plans to leverage Serendipity's technologies to enhance and diversify its current nuclease technologies. This will reportedly allow potential therapeutic applications in reverse transcriptase (RT) editing and insertion of exons or entire genes in vivo.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.